Literature DB >> 33040232

Clinical conditions needed to acquire sustained functional remission in rheumatoid arthritis patients.

Ryousuke Koizumi1,2, Kensuke Koyama3,4, Masanori Wako1, Tetsuro Ohba1, Yoshihiro Takayama1, Hirotaka Haro1.   

Abstract

OBJECTIVES: Treatments aimed at maintaining sustained clinical remission in rheumatoid arthritis (RA) patients have been recommended by several groups. Improvement and maintenance of functional status are also important for RA patients. The purpose of this study was to investigate the factors for maintaining long-term functional remission.
METHODS: RA patients with usual care without specific protocols were included. Disease activity score using 28-joint count C-reactive protein (DAS28-CRP), simplified disease activity index (SDAI) score, and Health Assessment Questionnaire Disability Index (HAQ-DI) score was calculated every 3 months for 1 year. Patients were divided into the HAQ-DI remission (REM) group and the HAQ-DI non-remission (NO-REM) group; time-averaged values of these parameters were compared between groups.
RESULTS: Of the 205 patients, 154 fulfilled the remission criteria. Time-averaged DAS28-CRP and SDAI score were significantly lower in the REM group than in the NO-REM group (1.66 vs 2.59, 3.54 vs 10.68, respectively; p < 0.001). Subsequent receiver-operating characteristic (ROC) analysis for estimation of remission indicated a cut-off value of 1.65 for time-averaged DAS28-CRP and 2.85 for time-averaged SDAI score.
CONCLUSIONS: Previous reports showed that fulfillment of clinical remission increases the possibility of functional remission; the probability of which is higher in patients with sustained clinical remission. Sustained clinical remission is required to achieve sustained functional remission; the criteria for clinical remission may be more stringent. Key Points • Sustained deep clinical remission was required to achieve sustained functional remission.

Entities:  

Keywords:  DAS28-CRP; Health Assessment Questionnaire Disability Index; Remission; Rheumatoid arthritis; SDAI

Mesh:

Substances:

Year:  2020        PMID: 33040232     DOI: 10.1007/s10067-020-05451-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

2.  Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis.

Authors:  Kumi Shidara; Ayako Nakajima; Eisuke Inoue; Daisuke Hoshi; Naoki Sugimoto; Yohei Seto; Eiichi Tanaka; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  J Rheumatol       Date:  2016-12-01       Impact factor: 4.666

3.  American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

4.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

5.  Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.

Authors:  Jon Thorkell Einarsson; Pierre Geborek; Tore Saxne; Lars Erik Kristensen; Meliha C Kapetanovic
Journal:  J Rheumatol       Date:  2016-04-01       Impact factor: 4.666

6.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Authors:  Josef S Smolen; Robert B M Landewé; Johannes W J Bijlsma; Gerd R Burmester; Maxime Dougados; Andreas Kerschbaumer; Iain B McInnes; Alexandre Sepriano; Ronald F van Vollenhoven; Maarten de Wit; Daniel Aletaha; Martin Aringer; John Askling; Alejandro Balsa; Maarten Boers; Alfons A den Broeder; Maya H Buch; Frank Buttgereit; Roberto Caporali; Mario Humberto Cardiel; Diederik De Cock; Catalin Codreanu; Maurizio Cutolo; Christopher John Edwards; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Laure Gossec; Jacques-Eric Gottenberg; Merete Lund Hetland; Tom W J Huizinga; Marios Koloumas; Zhanguo Li; Xavier Mariette; Ulf Müller-Ladner; Eduardo F Mysler; Jose A P da Silva; Gyula Poór; Janet E Pope; Andrea Rubbert-Roth; Adeline Ruyssen-Witrand; Kenneth G Saag; Anja Strangfeld; Tsutomu Takeuchi; Marieke Voshaar; René Westhovens; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2020-01-22       Impact factor: 19.103

7.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02

Review 8.  The determination and measurement of functional disability in rheumatoid arthritis.

Authors:  Frederick Wolfe
Journal:  Arthritis Res       Date:  2002-04-08

9.  Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.

Authors:  Helga Radner; Farideh Alasti; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2015-08-11       Impact factor: 5.156

10.  Patient's perspective of sustained remission in rheumatoid arthritis.

Authors:  Irazú Contreras-Yáñez; Guillermo Guaracha-Basañez; Daniel Ruiz-Domínguez; Virginia Pascual-Ramos
Journal:  BMC Musculoskelet Disord       Date:  2017-09-02       Impact factor: 2.362

View more
  1 in total

1.  Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis.

Authors:  Sebnem Ataman; Ismihan Sunar; Hatice Bodur; Meltem Alkan Melikoglu; Hasan Fatih Cay; Erhan Capkin; Ozgur Akgul; Remzi Cevik; Feride Gogus; Ayhan Kamanli; Fatma Gul Yurdakul; Gulcan Gurer; Ilker Yagci; Aylin Rezvani; Mehmet Tuncay Duruoz
Journal:  Rheumatol Ther       Date:  2021-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.